Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 December;59(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 December;59(4):411-9

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF LOCALLY ADVANCED AND ADVANCED PROSTATE CANCER


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 December;59(4):411-9

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Lymph-node relapsed prostate cancer management and PET-driven external beam radiotherapy: salvage or palliative treatment?

Vavassori V. 1, Alongi F. 2, D’agostino G. A. 3, Della Bosca E. 1, Scorsetti M. 3

1 Radiotherapy Unit, Humanitas Gavazzeni, Bergamo, Italy; 2 Department of Radiation Oncology, Sacro Cuore Hospital, Negrar, Verona, Italy; 3 Radiotherapy and Radiosurgery, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Milano, Italy


PDF  


New imaging modalities such as choline- positron emission tomography (PET) or PET/computed tomography (CT) may be useful to identify prostate cancer patients with small volume, limited nodal relapse (“oligo-recurrent”), potentially amenable to metastasis directed treatment (e.g. radiotherapy,) with the aim of long-term control of the disease, even in a setting traditionally considered prognostically unfavorable, so usually gone to palliative treatment.
This report reviews the diagnostic tools and the main published data about the role of PET or PET/CT driven radiation therapy, (not only for the diagnosis, but also for the plannig) in relapsed node prostate carcinoma, as an alternative therapeutic strategy than surgery or androgen deprivation therapy.

top of page

Publication History

Cite this article as

Corresponding author e-mail

vittorio.vavassori@gavazzeni.it